Minerva Neurosciences Accounts Payable

Minerva Neurosciences (NERV) currently reports a accounts payable of $1.4B as of June 2026. That compares with $900K in the prior-year period — up 161313.7% year over year. Use the charts on this page to explore Minerva Neurosciences's accounts payable history and peer comparisons.

Minerva Neurosciences's accounts payable increased from $900K to $1.4B — a 161313.7% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Minerva Neurosciences reported $1.4B in accounts payable as of June 2026. That compares with $900K in the prior-year period — up 161313.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $1.4B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Minerva Neurosciences, and consider following NERV for alerts when major investors trade the stock.

Minerva Neurosciences is classified in the Healthcare sector. On accounts payable, it currently shows $1.4B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NERV with unrelated industries.